Hepatocellular Carcinoma
Conditions
Interventions
Group A:transcutaneous electroacupuncture, TEA
Group B:sham transcutaneous electroacupuncture
Sponsors
Shanghai Changzheng Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Willing to sign the informed consent; 2. Aged 18-75, both sexes; 3. Clinical diagnosis of primary hepatocellular carcinoma; 4. Child-Pugh A/B liver function, ECOG PS score 0-1; 5. Barcelona lesions (BCLC) stage A, B and some C, suitable for TACE.
Exclusion criteria
Exclusion criteria: 1. History of other malignant tumors within 5 years 2. Taking analgesics, antidepressants, anti-epileptic drugs and other drugs within 6 months; 3. serious cardiovascular and cerebrovascular diseases; 4. diabetic blood glucose that cannot be controlled; 5. Cognitive dysfunction, aphasia, mental disorders or diseases that may affect patients' cooperation; 6. pregnant, preparingn for pregnancy or breastfeeding patients; 7. Severe liver dysfunction: Child-Pugh grade C liver function, serum bilirubin > 51.3 µmol/L, hepatic encephalopathy, refractory abdominal effusion or hepatorenal syndrome, etc. 8. Irreversible severe coagulopathy: INR > 1.5, platelet < 50 x10^9; 9. Complete tumor thrombus or thromboembolism of the main portal vein, with poor formation of collateral vessels; 10. Severe infection or complicated with active hepatitis that cannot be treated simultaneously; 11. Familiar with acupuncture treatment, acupoint selection or meridians; 12. Skin diseases affecting electrode fixation; 13. In the opinion of the researcher, it is not suitable for participants.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| VAS;Dose of morphine;Nausea and vomiting score;HRV;EGG;IL-6;NE;TNF-a;IL-1ß;NGF; | — |
Primary
| Measure | Time frame |
|---|---|
| VAS;the ratio of morphine use; | — |
Countries
China
Contacts
Public ContactWeihua Dong
Shanghai Changzheng Hospital
Outcome results
None listed